CPR builds on the proprietary antibody engineering technology developed by the Chugai Group in order to achieve our goals.
ESG at Chugai Group
Chugai Group conducts its business activities to fulfill its mission of benefiting the medical community and human health around the world.
Browse through the latest news and developments by CPR and the Chugai Group.
- Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Chugai’s Enspryng (Satraliazumab) Subcutaneous Injection 120 mg Syringe Approved in Japan for Neuromyelitis Optica Spectrum Disorder
- Phase III IPATential150 Study Evaluating Ipatasertib in Combination with Abiraterone and Prednisone/Prednisolone in Patients with Metastatic Castration-Resistant Prostate Cancer Meets One of Its Co-Primary Endpoint